Press Release Archives - Page 12 of 23

Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities

Tigris trial enrollment at 60 patients. TORONTO, Ontario – May 24, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today reported hosting an...

Spectral Medical Inc. Announces Director Resignation

TORONTO, Ontario – May 4, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Mr. Jim Funk has tendered his resignation from the Board...

Spectral Medical Announces Investor Update Conference Call

TORONTO, Ontario – April 6, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced details for the Company’s 2023 Investor Update conference...

Spectral Medical Announces the Opening of Two Additional Tigris Clinical Trial Sites

Reaches 16 total clinical trial sites for Tigris and expects two more opening around the end of Q1 TORONTO, Ontario – March 9, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for...

Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments

50 Patients Randomized to Date out of the 150 Total Target to be Enrolled Reports Significant Uptick in Screening and Enrollment Activities TORONTO, Ontario–January 12, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...

Spectral Medical Announces Strategic Joint Venture with Infomed to Accelerate Commercialization of DIMI and SAMI Dialysis Devices.

Spectral to receive a significant equity stake in the joint venture, while eliminating its need to fund future capital requirements for SAMI and DIMI TORONTO, Ontario–December 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.